Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with primary open-angle glaucoma or high eye pressure (ocular hypertension), as defined by the Early Manifest Glaucoma Trial criteria
- People aged 18 or older
- People who have signed a consent form agreeing to take part
- People who have been using one of these specific eye drop medications for 3 months or more: tafluprost 0.0015%, latanoprost 0.005% with BAK 0.2mg/ml, or latanoprost 0.005%
- People with high eye pressure who have never received any treatment for this condition (if in the untreated group)
- People who have no other eye diseases, and no history of other eye diseases that began before they started using eye pressure-lowering medication
Who may not be able to join:
- People who have had eye surgery in the last 6 months
- People who have had an active eye surface disease (unrelated to glaucoma or high eye pressure) within the last 6 months
- People who have used any eye drops other than those being studied in the last 3 months
- People who use preserved artificial tears (preservative-free artificial tears used no more than 4 times per day may be permitted, but must be stopped 5 days before joining the trial — confirm with trial site)
- People who have worn contact lenses in the last 4 weeks
- People with a mental or physical condition that would prevent them from completing the tests required by the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 983184734
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Inflammatory response in ocular surface secondary to prostaglandin use; Conjunctival cell phenotype and inflammatory infiltration; Changes in oxidative stress in the tear film
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.